Bringing precision medicine to the point of care

Precision Medicine by Flatiron is a suite of features that enables oncologists to understand and act on tumor biology to inform treatment and match patients to clinical trials. This offering helps bring precision medicine to the point of care.

The latest from Flatiron on the impact of precision medicine

- Industry challenges and opportunities for the integration of precision medicine tools at the point of care, The Journal of Precision Medicine publications Part 1 & Part 2
- Bringing actionable insights to the point of care as precision medicine involves, Flatiron Communities blog
- Enable precision medicine for every patient, Flatiron Communities blog

Molecular Profiling Integration in OncoEMR®

Streamline the molecular profiling test order process, minimizing submission delays and delays to patient care.

- Easily order tests within OncoEMR®, with fewer clicks and less data entry
- Track test order status with real-time updates
- Get your results returned directly to the patient’s chart and provider inbox, without leaving the EHR
- Currently available with Caris Life Sciences® and Foundation Medicine.

“"We really like the workflow — it’s a beautiful functionality where you can click on the result directly from the order form.”

Jackie Livesay MSN, RN
Lead Clinical Systems Analyst, West Cancer Center

CREATING IMPACT

Driving efficiency: Streamline workflows for molecular profiling tests

Driving actionability: Empower the use of genomic results in clinical practice

Driving insights: Bring more treatment options to patients
Streamlined Biomarker Screening in OncoTrials®

Efficiently match patients to biomarker-gated trials

- Clearly identify patients who have been tested for biomarkers
- Easily view trial-specific biomarker results and relevant details to better match patients to trials
- Reduce time spent on manual biomarker data entry

Inferred Genomic Testing Status in OncoTrials®

- Identify NGS-tested patients through a simplified search process
- Quickly find patients eligible for biomarker-gated trials based on integrated genomic results through the Molecular Profiling Integration and machine learning models